Information Technology
PHARMAGEST INTERACTIVE: H1 2017 Net Profit up 5.73%
Villers-lès-Nancy, 22 September 2017 - 6:30 p.m. (CET)
On 22 September 2017, PHARMAGEST INTERACTIVE's Board of Directors, chaired by Thierry CHAPUSOT, reviewed and adopted the financial statements for the six-month period ended 30 June 2017. These interim consolidated financial statements were subject to a limited review by the Statutory Auditors.
PHARMAGEST Group's revenue was up 13.38% from last year's same period. Excellent performances by each of the four Divisions contributed to PHARMAGEST Group's overall development.
Operating profit rose 6.35% to €16.60 million.
and Net Profit attributable to the Parent grew 5.41% in relation to the same period in 2016.
At 30 June 2017, Basic Earnings per Share amounted to €0.70, up from €0.67 one year earlier.
At 30 June 2017, PHARMAGEST Group's net cash position had increased to €69.63 million, compared to €61.71 million at 30 June 2016.
Equity attributable to the Parent at 30 June 2017 amounted to €101 million.
PHARMAGEST Group is confident that its targets will be met and confirms that its business development efforts remain on track.
In accordance with its strategic ambitions, PHARMAGEST Group is committed to being an even more active stakeholder in contributing to modernization of the healthcare systems in France and Europe. With this objective, it will continue to develop its "patient-centred" platform by proposing a dedicated global ecosystem.
In addition, with the recent acquisition of AXIGATE, PHARMAGEST Group is today the only player capable of addressing throughout Europe an offering for coordinated care across "non-hospital and hospital" pathways. Its ambitions for international development has thus been strengthened and PHARMAGEST Group is now very well-positioned to pursue discussions with other key European partners.
Listed on Euronext Paris(TM) - Compartment B
Indices: CAC SMALL and CAC All-Tradable par inclusion
Eligible for the Long-Only Deferred Settlement Service (SRD)
ISIN: FR 0012882389 - Reuters: PHA.PA - Bloomberg: - PMGI FP
www.pharmagest.com
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti